Redx Pharma plc Re: Porcupine inhibitor and cancer immunotherapy (1362K)

TIDMREDX

RNS Number : 1362K

Redx Pharma plc

19 September 2016

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company")

Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy

Redx, the drug development company, is pleased to confirm that its lead cancer treatment, the Porcupine inhibitor (RXC004), has a potential role in cancer immunotherapy. Redx scientists have demonstrated that the Porcupine inhibitor could have a crucial role in improving the immune system response of some cancer patients when used in combination with an existing immunotherapy, anti-programmed cell death-1 (anti-PD-1).

Anti-PD-1 therapy activates the immune system to recognise and attack tumours. While treatment with PD-1 inhibitors, also known as Checkpoint inhibitors, is a significant breakthrough in cancer treatment, not all patients respond.

Redx has been testing a combination therapy that uses both the Porcupine inhibitor RXC004 and an anti-PD-1 antibody in a cancer model. The data demonstrates that the combination therapy significantly improves the ratio of favourable T-cells, which attack tumours, to the immunosuppressive T-cells that allow tumours to grow unrecognised, when compared to only using an anti-PD-1 therapy. This suggests that a combination therapy could potentially improve patient response rates.

Redx's novel, potent small molecule Porcupine inhibitor has already shown, in disease models, that it has potential as a stand-alone therapy for difficult to treat cancers, such as pancreatic cancer.

As previously reported, first-in-human studies for the Porcupine inhibitor, initially as a stand-alone therapy, are expected to commence early in 2017. In addition, Redx is now evaluating opportunities for combination therapies.

Neil Murray, CEO of Redx, commented:

"The results so far from our Porcupine inhibitor, RXC004, have been very impressive, with important implications for difficult to treat cancers, such as pancreatic cancer.

Over the past few years, significant progress has been made in harnessing the ability of the immune system to attack cancer. We are very pleased that our new findings confirm that our lead cancer treatment, the Porcupine inhibitor RXC004, now also has a potentially crucial role in enhancing existing cancer immunotherapy treatments.

Our Porcupine program has progressed from concept to moving towards first-in-human clinical trials in a little under three years, which is a remarkable achievement and evidence of our commercially disciplined approach and outstanding scientific capabilities."

For further information, please contact:

 
  Redx Pharma Plc 
  Neil Murray, Chief Executive             T: +44 151 
                                            706 4747 
  Karl Hård, Head of Investor         T: +44 7491 
   Relations &                              651 406 
   Corporate Communications 
   Company website: redxpharma.com 
 
    Cantor Fitzgerald Europe (Nomad        T: +44 020 
    & Broker)                              7894 7000 
  Phil Davies / Michael Reynolds 
                                            T: +44 020 
    KTZ Communications                       3178 6378 
  Katie Tzouliadis/ Viktoria Langley/ 
   Emma Pearson 
 

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhea, bone tumours, skin, brain, breast, pancreatic and blood cancers.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSFMEFAFMSESU

(END) Dow Jones Newswires

September 19, 2016 02:01 ET (06:01 GMT)